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Summary
 
The transgenic (tg) expression of interleukin (IL)-4 under the control of a major histocompati-
bility complex (MHC) class I promoter leads to B cell hyperactivity in mice, characterized by
increased B cell surface MHC class II and CD23 expression, elevated responsiveness of the B
cells to polyclonal ex vivo stimulation, and increased immunoglobulin (Ig)G1 and IgE serum
levels. Tg mice develop anemia, glomerulonephritis with complement and immune deposition
in the glomeruli, and show increased production of autoantibodies. Treatment of IL-4 tg mice
with anti-IL-4 neutralizing antibodies protected the mice from disease development, showing
that IL-4 was responsible for the observed disorders. Deletion of superantigen responsive au-
toreactive T cells in the IL-4 tg mice was normal and treatment of mutant mice with deleting
anti-CD4 antibodies failed to ablate the onset of autoimmune-like disease, suggesting that
CD4
 
1
 
 T cells were not the primary cause of the disorders. Furthermore, the deletion of B cells
reacting against MHC class I molecules was also normal in the IL-4 tg mice. Therefore the
most likely explanation for the increased production of autoantibodies and the autoimmune-
like disorders is that IL-4 acts directly on autoreactive B cells by expanding them in a poly-
clonal manner. Taken together our results show that inappropriate multi-organ expression of
IL-4 in vivo leads to autoimmune-type disease in mice.
 
A
 
utoimmune diseases are caused by incomplete deletion
and inappropriate peripheral activation of self-reactive
T and/or B cells. Self-reactive T cells can cause autoim-
mune diseases either directly by interacting with self-target
cells and/or organs, as seen in autoimmune diabetes, or in-
directly by activating self-reactive B cells. The autoreactive
B cells then in turn produce autoantibodies which can cause
or contribute to autoimmune disorders such as rheumatoid
arthritis, systemic lupus erythematosus (SLE)
 
1
 
, multiple scle-
rosis, or myasthenia gravis (1–3). Autoreactive T and B cells
are present in normal animals and humans showing that
factors other than self recognition per se are involved in the
development of autoimmune disease (4–7). Even though
human autoimmune disorders have been widely studied,
and several and diverse animal models are available, it is
known only in a few cases why autoreactive T or B cells
become activated and manifest themselves. One important
mechanism in the induction and maintenance of tolerance
is the deletion of self-reactive T and B cells by apoptosis.
Experiments with transgenic (tg) mice overexpressing the
proto-oncogene bcl-2, which inhibits apoptosis, support
this view. Some bcl-2 tg mouse strains develop glomerulo-
nephritis and show inhibition of T and B cell apoptosis (8, 9).
Another factor shown to be involved in apoptosis of T and
B cells is fas.
 
 
 
Mice with deficient expression of either fas or
fas-ligand (lpr, lpr
 
cg
 
, and gld mice) develop SLE-like symp-
toms (1, 2). Recent in vitro findings suggested that IL-4
can rescue apoptotic B cells from cell death (10–15). The
expression of IL-4 in vivo could therefore lead to the sur-
vival and activation of autoreactive B cells and thus possibly
contribute to the development of autoimmune disease.
Whereas Th2 immune responses with highly localized but
tightly regulated IL-4 production do not seem to cause au-
toimmune disease, it is possible that aberrant and continu-
ous IL-4 secretion could lead to the development of au-
toimmune disorders either through polyclonal B cell
activation, or by selectively rescuing apoptotic self-reactive
B cells from cell death. To test this hypothesis we analyzed
whether constitutive in vivo expression of IL-4 would lead
to the production of autoantibodies and autoimmune dis-
ease. For this purpose we used tg mice expressing IL-4 un-
 
1
 
Abbreviations used in this paper:
 
 AIHA, autoantibody-induced hemolytic
anemia; ANA, anti-nuclear antigen; ASMA, anti-smooth muscle antigen;
ENA, endonuclear antigen; MMTV, murine mammary tumor viruses;
SLE, systemic lupus erythematosus; tg, transgenic.
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der the control of a class I promoter leading to a low level
of IL-4 production in virtually all cell types (16, 17). The
use of this promoter ensures that autoreactive B cells un-
dergoing negative selection are subject to the action of IL-4.
In this report we show that IL-4 tg mice have elevated au-
toantibody titers and suffer from autoimmune-type disease.
 
Materials and Methods
 
Mice
 
The IL-4 tg mice were originally established from B6C3F1/
CrlBR mice and then bred with B6C3F1 mice (16). The mice
used in this report were backbred eight generations with C3H
mice. Littermates were used as wild-type controls. The CTLA-4 tg
mice (18) were obtained from Peter Lane (Basel Institute of Im-
munology, Basel, Switzerland) and backbred eight generations on
C57Bl/6 genetic background. To establish IL-4/CTLA-4 double
tg mice, heterozygous IL-4 tg males were bred with heterozygous
CTLA-4 tg females. The offspring were tested as previously de-
scribed (16, 19) and non-tg or single-tg mice were used as control
animals. The 3-83
 
m
 
 tg animals (H-2
 
d
 
 and H-2
 
k
 
) were obtained
from K. Buerki (Sandoz, Basel, Switzerland). IL-4/3-83
 
m
 
 double-
tg mice were generated by breeding heterozygous IL-4 tg males
with heterozygous 3-83
 
m
 
 tg females (H-2
 
k
 
). The offspring were
tested using PCR technology. All animals were maintained under
conventional conditions in an isolation facility.
 
Cell Preparations and FACS
 
Ò
 
 Analysis
 
Spleens and lymph nodes were rubbed through a steel mesh
and the cell debris excluded. Bone marrow cells were obtained by
washing the cells out of the bones with a gauze needle mounted
on a 1-ml syringe. The cells were washed and then microscopi-
cally counted in a thoma chamber. B cells from the spleen were
obtained by depleting T cells through the addition of monoclonal
anti-Thy-1 antibodies and subsequent complement lysis (16). B
cells from the bone marrow were isolated by incubating 1 
 
3 
 
10
 
8
 
cells/ml with anti B220 coated magnetic beads (1:10 in BSS/1%
BSA) for 15 min at 4
 
°
 
C, and then running the suspensions over a
magnetic column and eluting the B220
 
1
 
 cells according to the
manufacturer’s instructions (Miltenyi Biotech, Bergisch Gladbach,
Germany). The reactivity of cell populations with monoclonal anti-
bodies was analyzed by immunofluorescence, using two- and three-
color analysis performed with a FACScan
 
Ò
 
 (Becton Dickinson,
Mountain View, CA). The FITC-labeled antibodies used were anti-
CD8 (Ly-2), CD23 (B3B4), and Thy-1.2 (53-2.1) (all purchased
from PharMingen, San Diego, CA). The clone 13/4 reacting with
IA
 
k
 
 was kindly provided by G. Hämmerling (Deutsches Krebsfors-
chungs-Zentrum, Heidelberg, Germany). The FITC-labeled anti-
body reacting with the 3-83
 
m
 
 tg Ig receptor (mAb 54.1 from the rat)
was a generous gift from K. Buerki. The purified anti-IL-4 receptor
antibody (clone mIL-4R-M2) was obtained from Immunex (Seattle,
WA). Phycoerythrin-labeled antibodies used were anti-CD4 (L3T4),
CD8 (Ly-2) (both PharMingen), and B220 (RA3-692) (Serva,
Heidelberg, Germany). Biotin labeled antibody used was anti-
 
ab
 
TCR in conjunction with streptavidin cychrome (both from
PharMingen). Specificity of antibody binding was controlled by
staining with isotype-matched control antibodies.
 
Proliferation Assays
 
Splenic B cells.
 
2 
 
3 
 
10
 
5
 
 T cell–depleted spleen cells/well were
incubated in RPMI medium (Gibco BRL, Berlin, Germany) sup-
 
plemented with 5% fetal calf serum and additives (RPMI
 
1
 
) in the
presence of medium alone, anti-
 
m
 
F(ab
 
9
 
)
 
2
 
 antibodies (25 
 
m
 
g/ml;
Jackson Immuno Research Labs. Inc., West Grove, PA), or LPS
(10 mg/ml, Hoechst, Germany) for 40 h. 11B11 (anti IL-4 mAb,
10 
 
m
 
g/ml, kindly provided by Dr. G. LeGros [Malaghan Institute
of Medical Research, Wellington, New Zealand]) was also added
into parallel cultures at the onset of the experiments. To deter-
mine the amount of proliferation the cells were then pulsed with
[
 
3
 
H]thymidine (0.25 mCi/well), 2 Ci (mmol) for 16 h. The in-
corporated radioactivity was measured on a 
 
b
 
-plate (Pharmacia).
 
Bone Marrow–derived B Cells.
 
1 
 
3 
 
10
 
5
 
 bone marrow–derived
B cells were incubated with 3 
 
3 
 
10
 
4
 
 CD40 ligand transfected (20)
or untransfected (both mitomycin-treated) L929 fibroblasts in the
presence or absence of 11B11 (anti IL-4 mAb, 10 
 
m
 
g/ml) for 40 h.
The proliferation was measured by pulsing the cells for the last 16 h
with [
 
3
 
H]thymidine (0.25 mCi/well) and incorporated radioac-
tivity measured as above.
 
Detection of Autoantibodies in the Serum
 
Anti-nuclear antigen (ANA) and anti-smooth muscle antigen
test (ASMA). Serum from IL-4 tg and littermate control mice
were serially diluted in PBS. The diluted serum was incubated
with sections containing Hep2 cells (ANA) or rat gut and stom-
ach (ASMA; both from Biolab, Germany) at rt for 1 h. After
washing three times with PBS the sections were stained with
FITC-conjugated rat anti–mouse Ig (Dianova, Hamburg, Germany).
The binding of antibodies was visualized and scored using a fluores-
cent microscope. A serum was scored autoantibody positive when
the titer was greater or equal to 1/30 (ANA, maximum detected titer
1/200) or 1/10 (ASMA, maximum detected titer 1/100).
 
Detection of Autoreactive Monoclonal Antibodies
 
Whole spleen from 4 IL-4 tg and 3 littermates (mice were 4-5
wk of age) were fused with P3X63.Ag8.653 myeloma cells with
the help of polyethyleneglycol (Sigma Chem. Co., St. Louis,
MO). Hybridomas were grown on 96-well flat bottom microtiter
plates (Falcon, Oxnard, CA) in selection medium (RPMI
 
1
 
, 1
 
3
 
azaserine-hypoxanthine, 2.5% HECS; Sigma) for 1 wk and the
supernatants tested in an ELISA assay for antibodies against endo-
nuclear antigen (ENA-assay). In brief, 96-well microtiter plates
were coated with calf thymus extract (Inova Diagnostics, San Di-
ego, CA) in coating buffer (1:100 dilution in 0.05 M carbonate
buffer, pH9.6), washed with ELISA buffer (PBS/0.05% Tween
20; Sigma), and then blocked with PBS/1% BSA for 1 h. 50 
 
m
 
l of
each supernatant was incubated in doublets on the microtiter
plates for 2 h at room temperature. Human serum containing au-
toantibodies against endonuclear antigens was used as a positive
control; RPMI
 
1
 
 medium was used as a negative control. After
washing, autoreactive antibody binding was detected with goat
anti–mouse Ig or goat anti-human Ig coupled to alkaline phos-
phatase (Southern Biotech., UK) followed by substrate solution
(1 mg/ml paranitrophenylphosphate, 0.02% NaN
 
3
 
, 0.08% MgCl
 
2
 
,
9.7% (vol/vol) diethanolamine; all Sigma). The color reaction was
measured at OD
 
405
 
 after 30–50 min with an ELISA reader (Biorad,
Munich, Germany). Supernatants were considered positive when
the ratio of the absorbency between the supernatant and the nega-
tive control was equal to or greater than 2.0.
 
Treatment of Mice with Anti-CD4 and Anti-IL-4 
Antibodies
 
3–4-d-old mice (6 litters) were treated either for 8 wk with
anti-CD4 depleting antibodies (19 mice) or for 7 wk  with anti- 
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IL-4 neutralizing antibodies (11B11) (16 mice). The mice were
injected either with 1 mg of anti-CD4 once weekly or with 1 mg
of 11B11 every 3 d, i.p. Less than 2% residual CD4 T cells could be
detected after the anti-CD4 treatment. This was shown by triple
staining using anti-CD4 PE, anti-CD8 FITC, and anti-
 
ab
 
TCR
biotin/Strep-Chychrome. Individual IL-4 tg and wild-type mice
were identified using PCR-technology (16), after sacrifice. The
anti-CD4 antibodies (clone GK 1.5) and anti-IL-4 neutralizing
antibodies (11B11) were generously provided by Dr. G. LeGros.
 
Hematology
 
Reticulocytes were identified by incubating fresh whole blood
with 1% Brilliant cresyl blue in citrate saline at 37
 
8
 
C. Smears were
prepared after 20 min and examined under oil immersion. The
percentage of reticulocytes present in the blood was evaluated by
counting 300 cells/smear. Hematocrit was measured by the mi-
crohematocrit method using heparinized capillary tubes. Bilirubin
levels were quantified with a bilmeter (Mochida, Tokyo, Japan)
using capillary tubes.
The coombs test was performed using standard technology and
goat anti–mouse or rabbit anti–mouse total Ig (both from Dako
Corp., Carpinteria, CA) with serial dilutions.
 
Immunohistology
 
Paraffin sections (2 
 
m
 
m) of kidney tissue obtained from normal
and IL-4 tg mice were digested with bacterial protease XXIV
(Sigma) for 10 min at 37
 
°
 
C before incubating the slides with anti-
bodies for 1 h at room temperature. Frozen, acetone-fixed tissue sec-
tions were also stained with antibodies for 1 h at room temperature
omitting the predigestion step. Antibodies used were: peroxidase-
conjugated rabbit anti–mouse Ig (anti-total Ig; Dako Corp., Carpin-
teria, CA); peroxidase-conjugated sheep anti–mouse IgA (Serotec,
Oxford, England), biotinylated rat anti–mouse IgM, and IgG2a
(both PharMingen), biotinylated rat anti–mouse IgE (Ciba Geigy,
Basel, Switzerland), peroxidase-conjugated sheep anti–mouse IgG1
(Serotec), FITC conjugated goat anti–mouse complement 3 (Nor-
dic, Tilburg, NL). All antibodies were diluted in 1% BSA/Tris-
buffer. Endogenous peroxidase activity was inhibited with 0.3%
H
 
2
 
O
 
2
 
 in Tris-buffered saline for 10 min. Incubation of biotiny-
lated antibodies was followed by application of peroxidase-conju-
gated streptavidin (BioGenex, San Ramon, CA) for 30 min. The
substrate diaminobenzidine was added until the desired staining
intensity occurred. After counterstaining with hematoxylin, the
sections were dehydrated and mounted in DPX. For control ex-
periments, biotinylated primary antibodies were omitted and per-
oxidase-conjugated antibodies were substituted with peroxidase
conjugated rabbit anti–swine immunoglobulins (Dako). Blood
smears were prepared, air-dried and fixed in acetone for 10 min.
The same method as for the frozen sections was used to detect
autoantibody binding to RBCs (see above).
 
Microscopy
 
Light Microscopy.
 
Tissues were fixed in 10% phosphate buff-
ered formalin for 24 h, and embedded in paraffin wax. 2–3-
 
m
 
m
sections were cut and stained with hematoxylin and eosin.
 
Transmission Electron Microscopy.
 
Renal cortex was fixed in
half strength Karnovsky fixative for 1 h, transferred to cacodylate
buffered osmium tetroxide, embedded in Epon 812, and ultra-
thin sections were cut. Grids were viewed in a Siemens (Munich,
Germany,) 102 transmission electron microscope following stain-
ing with lead citrate and uranyl acetate.
 
Results
 
Pathological Disorders in IL-4 Tg Mice.
 
IL-4 tg mice of
this particular line have a very high mortality rate (Fig. 1 
 
A
 
)
and suffer from severe anemia as seen by the dramatic de-
crease in hematocrit (Fig. 1 
 
B
 
) and increase in reticulocyte
numbers in the blood (Fig. 1 
 
C
 
). Furthermore, IL-4 tg
mice showed extramedullary hematopoiesis in spleen and
liver with elevated bilirubin levels in the blood (data not
Figure 1. Anemia in the IL-4 tg mice. (A) Survival rate of IL-4 tg
mice. IL-4 tg (n = 31) and littermate control mice (n = 20) were moni-
tored daily for 12 wk  and the death of mice recorded. Shown is the sur-
vival rate of the mice in percentage. (B and C) Hematocrit counts and per-
centage of reticulocyte numbers in the blood of 4- and 12-wk-old IL-4 tg
and control mice. 
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shown). These observations suggested that the mice de-
velop an autoantibody-induced hemolytic anemia (AIHA).
Staining of blood smears with rabbit anti–mouse Ig re-
vealed that some of the tg mice with the most severe ane-
mia had detectable levels of antibodies bound to their
erythrocytes. However, a coombs test using erythrocytes
from IL-4 tg mice and goat or rabbit anti–mouse total Ig
failed to detect autoantibodies binding to the erythrocytes
from the IL-4 tg mice (data not shown).
Kidneys of IL-4 tg mice showed progressive glomerular
damage with complement and Ig deposition in glomeruli
(Fig. 2) and developed progressive glomerular hypertrophy
and glomerulosclerosis. The antibodies present in the kid-
neys of IL-4 tg mice were of the IgM, IgG1, IgG2a, and
IgA but not IgE isotypes (data not shown). On electron
microscopy the deposits were predominantly localized to
subendothelial and mesangial areas (data not shown). Most,
but not all, of the glomeruli in the kidneys of IL-4 tg mice
showed signs of damage. IL-4 tg mice showing signs of
wasting syndrome (
 
n
 
 = 6) had an average 10-fold decrease
in urine volume (measured over 24-h period) and a 6-fold
increase in urinary protein excretion as compared to litter-
mate control mice (Rüger, B., unpublished observation).
 
Autoantibody Production in the IL-4 Tg Mice.
 
The associ-
ation of autoimmune disease with elevated autoantibody ti-
ters lead us to analyze whether mutant mice had elevated
levels of autoantibodies. For this purpose an ANA and
ASMA test was used. Serum from IL-4 tg and control mice
were incubated with sections of Hep 2 cells (ANA test) or
rat gut (ASMA test). Bound autoantibodies were visualized
by rat anti–mouse Ig-FITC under a fluorescence micro-
scope. Fig. 3 shows a typical positive (
 
A
 
) and negative (
 
B
 
)
ANA or ASMA staining. Antibody titers equal or greater to
1/30 (ANA) or 1/10 (ASMA) were scored positive. Fig. 4
summarizes the results of the ANA tests. The frequency of
mice having detectable amounts of autoantibodies against
Figure 2. Immune deposits in
the kidneys of IL-4 tg mice. The
kidneys of an IL-4 tg (A) and
control mouse (B) were fixed in
formalin and stained with perox-
idase conjugated rabbit anti–mouse
total Ig. Ig binding was visual-
ized through the addition of di-
aminobenzidine. Shown is a rep-
resentative example of immune
deposition detected in IL-4 tg
mice (n 5 20). g, glomerulus.
Figure 3. ANA and ASMA test. The sections containing Hep 2 cells
(ANA) and rat gut (ASMA), were incubated with different concentrations
of mouse serum (shown is the result using a 1/30 dilution). The binding
of antibodies to the autoantigens was then detected by incubating the sec-
tions with rat anti–mouse Ig conjugated with FITC and analyzed under a
fluorescence microscope. Shown is a typical positive ANA and ASMA
staining using serum from a tg mouse (A), and a negative staining (B), us-
ing serum from a wt mouse.  
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nuclear as well as smooth muscle antigens (data not shown)
were threefold higher in IL-4 tg mice than in littermate
control mice both in younger and older mice. The average
autoantibody titer of IL-4 tg mice scoring positive in both
ANA and ASMA test was about two- to threefold higher
than in littermate controls. Furthermore, there was no cor-
relation between high total Ig titers and autoantibody pro-
duction in IL-4 tg mice. In contrast, most of the control
mice with the highest autoantibody titers also had the high-
est total Ig serum levels (data not shown).
To assess whether autoantibody production in IL-4 tg mice
was due to the presence of more autoantibody producing
B cells, B cell hybridomas from pooled spleens of four IL-4
tg and three control mice (aged between 4–5 wk) were es-
tablished and analyzed for autoantibody production using
an anti-ENA test. Out of 1,064 tested IL-4 tg-hybridomas
9.1% scored positive for autoantibody production versus
only 1.3% from 586 analyzed control-hybridomas. This
was a sevenfold increase in the frequency of hybridomas
producing autoantibodies against endonuclear antigens in
the IL-4 tg mice as compared to littermate control mice.
Numbers of Ly1
 
1
 
 B cells which are often associated with
the production of autoantibodies (21) were not elevated in
the lymph nodes and peritoneal cavity of the IL-4 tg mice
as compared to control mice. This suggests that Ly1
 
1
 
 B
cells were not the major source of autoantibodies in the
mutant mice (data not shown).
 
Constitutive Expression of IL-4 In Vivo Leads to Polyclonal B
Cell Activation.
 
Autoantibody production is often associ-
ated with polyclonal B cell activation (22, 23). B cells from
the spleen, lymph node and bone marrow of IL-4 tg mice
express high levels of MHC class II and increased levels of
CD23, indicating polyclonal in vivo activation (Fig. 5 
 
A
 
).
To investigate whether the observed phenotype also corre-
lates with a greater responsiveness to B cell activators, we
stimulated B cells from lymph nodes with LPS and anti-
 
m
 
F(ab
 
9
 
)
 
2
 
 antibodies. Fig. 5 
 
B
 
 shows that B cells from IL-4
tg mice proliferated more strongly in response to LPS and
anti-
 
m
 
F(ab
 
9
 
)
 
2 stimulation than did B cells from littermate
controls. Furthermore, splenic B cells from tg mice still
showed proliferation to anti-mF(ab9)2 at concentrations where
normal B cells were no longer reactive (16). To assess
whether IL-4 also had a costimulatory effect on B cells acti-
Figure 4. Percentage of IL-4 tg and littermate control mice with au-
toantibodies in their serum binding to nuclear antigens. The serum of the
different mice were analyzed for the presence of autoantibodies against
nuclear antigens in an ANA test. Shown are the results using a 1/30 se-
rum dilution.
Figure 5. Hyperreactivity of B cells from the IL-4 tg mice. (A) Upreg-
ulation of surface MHC Cl II and CD23 expression and enlargement of tg
B cells. Spleen cells were isolated and then stained with antibodies against
B220, MHC CL II, and CD23. Experiments were repeated six times with
similar results. (B) [3H]Thymidine uptake from B cells from the spleen of
IL-4 tg and littermate control mice stimulated with LPS and anti-m
F(ab9)2 antibodies. 2 3 105 B cells per well were incubated with medium,
LPS (10 mg/ml) and anti-m F(ab9)2 antibodies (10 mg/ml) in the absence
or presence of 10 mg/ml anti-IL-4–neutralizing antibody (11B11) for 40 h,
pulsed for the last 16 h of the culture period, and then harvested. Mean
[3H]thymidine uptake of triplicates and standard deviations are shown
representative of three separate experiments. (C) B cells from the bone
marrow of IL-4 tg and control mice stimulated with CD40 ligand trans-
fected L cells. 1 3 105 B cells from the bone marrow of IL-4 tg and control
mice were incubated with 3 3 104 CD40 ligand–transfected and –untrans-
fected L929 fibroblasts (mitomycin D treated) in the absence or presence
of 10 mg/ml anti-IL-4 neutralizing antibody (11B11). The proliferation
assay was performed as described above.334 Autoimmune-type Disorders in IL-4 Transgenic Mice
vated through the interaction of CD40 with CD40 ligand,
we isolated B cells from the bone marrow and activated
them with CD40 ligand–transfected L929 fibroblasts (20).
Again, B cells from IL-4 tg mice responded more vigor-
ously than did B cells from controls (Fig. 5 C). The addi-
tion of anti-IL-4 neutralizing antibodies to the B cell cul-
tures (Fig. 5, B and C) from the IL-4 tg mice had no
negative effect on the proliferation of the B cells. This shows
that the B cells from the IL-4 tg mice have been activated
in vivo and not by tg-derived IL-4 in vitro. Taken together
these results, and previously published data (16), support
the costimulatory effect of tg IL-4 expression on B cells in
vivo leading to a constitutive activation of B cells in the
IL-4 tg mice. Interestingly, this polyclonal B cell activation
did not lead to a strong increase in total Ig levels in the se-
rum of tg mice, where the average amount of total Ig was
only about two- to threefold increased (data not shown).
However, IgG1 and especially IgE levels were elevated (16).
Negative Selection of Superantigen-reactive T Cells and Self-
reactive B Cells Is Normal in IL-4 Tg Mice. Previously pub-
lished data showed that the IL-4 tg mice used in this study
have a perturbed T cell development in the thymus and the
periphery (16, 17). To assess if these abnormalities lead to
the generation of more autoreactive T cells, we analyzed
whether the mutant mice deleted self-reactive T cells as ef-
ficiently as control mice. For this purpose the negative
selection of T cells in thymus and lymph nodes of IL-4 tg
mice was analyzed. The IL-4 tg mice used in this study
were backbred for eight generations onto the C3H genetic
background and therefore, expressed MHC class II molecules
of the IE haplotype, and carried the murine mammary tu-
mor viruses (MMTV) which, in association with IE (24, 25),
are responsible for deleting Vb3, 5 and 111 T cells. Table 1
shows that the IL-4 tg mice delete T cells expressing the
TCR elements Vb3, 5 and 11 in the thymus and in the
lymph nodes to a similar extent as did littermate controls.
As expected, the control Vb6 element was not affected by
the deletion.
To address the question whether the deletion of self-
reactive B cells is normal in the IL-4 tg mice we crossed the
IL-4 tg mice (H-2k) with tg mice expressing genes for the
variable region of an anti-H-2k antibody (3-83m tg mice)
(30). F1 offspring were typed by using PCR technology.
The B cells in the bone marrow, lymph nodes, and spleen
of the 3-83m tg and 3-83m 3 IL-4 double tg mice were
double stained with anti-B220 and anti-3-83m idiotype an-
tibody (clone 54.1). FACSÒ analysis of the different lym-
phoid organs revealed that ,1.0% of B2201 cells expressed
the 3-83m idiotype in both the 3-83m tg and 3-83m 3 IL-4
double tg mice (Table. 2). Using the same staining protocol
B2201/3-83m1 double positive cells were readily detected
in the bone marrow, lymph nodes and spleens of 3-83m tg
mice of a non deleting background (30 and Table 2). These
results show that IL-4 tg mice delete self-reactive B cells to
a similar extent as non tg mice.
Table 1. Negative Selection of CD31 T Cells Expressing Vb3, 5, and 11 in the Thymus and Lymph Nodes of Control and IL-4 tg Mice
TCR Vb
elements
Thymus Lymph nodes
WT
C57B1/6 (IA)
WT
C3H (IE)
IL-4 tg
C3H (IE)
WT
C57B1/6 (IA)
WT
C3H (IE)
IL-4 tg
C3H (IE)
Vb3 6.9 6 1.4 1.8 6 0.6 0.7 6 0.3 1.9 6 0.7 0.3 6 0.1 0.5 6 0.3
Vb5 7.6 6 0.7 1.2 6 0.7 1.7 6 0.7 4.9 6 1.1 1.5 6 0.4 0.9 6 0.4
Vb6 6.7 6 1.8 7.9 6 2.4 10.5 6 3.1 7.1 6 1.5 10.1 6 2.5 12.3 6 3.4
Vb11 5.2 6 1.1 1.9 6 0.4 1.1 6 0.4 4.5 6 1.0 2.1 6 0.4 1.4 6 0.3
Negative selection of CD31 T cells expressing the TCR elements Vb3, 5, and 11 in the thymus and lymph nodes of control and IL-4 transgenic
mice. Thymocytes and lymph node cells from five IL-4 transgenic and five control mice (littermate and C57B1/6 mice), between the ages of 5-6
wk, were stained with monoclonal antibodies against CD3, Vb3, 5, 6, and 11. Shown are the mean percentages and standard deviation of CD31
cells in the thymus and lymph nodes expressing the different TCR-Vb elements.
Table 2. IL-4 Transgenic Mice Delete Self-reactive B Cells Reacting 
to MHC Class I Molecules (H-2k) as Efficiently as Control Animals
Lymph nodes Spleen Bone marrow
3-83mtg
(H-2d) 12.2 32.8 20.5
3-83mtg
(H-2k) ,1 ,1 ,1
3-83m 3 IL-4tg
(H-2k) ,1 ,1 ,1
The cells in the bone marrow, lymph nodes and spleen of the 3-83m
transgenic (either of the H-2k or H-2d haplotype) and 3-83m 3 IL-4
double transgenic mice (H-2k) were double stained with anti-B220 and
anti-3-83m idiotype antibodies (clone mAb 54.1). Shown are the per-
centages of B2201 cells expressing the anti H-2k idiotype in the lym-
phoid organs of the different groups of mice analyzed, representative for
two separate experiments.335 Erb et al.
Treatment of IL-4 Tg Mice with Depleting Anti- CD4 and
Neutralizing Anti-IL-4 (11B11) Antibodies and Analysis of
Crosses between IL-4 Tg Mice and Tg Mice Expressing a Soluble
CTLA-4 Human Ig Fusion Protein. Even though negative
selection of autoreactive T cells seems to have been normal
in the IL-4 tg mice, it is possible that activated autoreactive
B cells could interact with a small number of residual au-
toreactive T cells. These T cells could then further enhance
the production of autoantibodies by providing help to au-
toreactive B cells, thus causing the autoimmune disorders.
To address this question, we treated 11 tg and 8 control
mice with anti-CD4 for 8 wk with a weekly dose of 1 mg
of antibodies injected i.p. (starting at 3–4 d of age). Less
than 2% residual CD4 T cells could be detected after the
antibody treatment (data not shown). Fig. 6 A shows that
75% of the CD4 depleted IL-4 tg mice survived versus
only 45% in the untreated age matched control mutant
mice. However, the increased survival was only reflected
by a marginal increase in hematocrit (0.33 6 0.6 in treated
mice versus 0.25 6 0.7 in untreated mice). The treated con-
trol mice had similar hematocrit counts to untreated con-
trols showing that the injection of anti-CD4 antibodies had
no direct effect on hematocrit counts (data not shown). In-
Figure 6. Survival rate of IL-4 tg mice after in vivo anti-CD4 (A) and
anti-IL-4 neutralizing antibody (B) treatment. At 1 wk of age IL-4 tg and
littermate control mice were injected with anti-CD4 antibodies (tg: n 5
11; wt: n 5 8) for 8 wk and anti-IL-4 neutralizing antibodies (11B11) for
7 wk (tg: n 5 7; wt: n 5 9). During this time the numbers of dead mice
were recorded. Shown are the survival rates of treated versus untreated
control and IL-4 tg mice.
Table 3. Severity of Autoimmune Type Disorders Detected
in Control and IL-4 tg Mice, Crossed with CTLA-4 tg Mice
or Treated with Anti-IL-4 or Anti-CD4 Ab
Anemia Glomerulonephritis
Ig deposits
in the kidneys
Control mice
untreated 22 2
CTLA-4 tg mice
untreated 22 2
IL-4 tg mice
untreated 111 111 111
Control mice
anti-CD4
treated 22 2
Control mice
anti-IL-4
treated 22 2
Control mice 3
CTLA-4 tg
crosses 22 2
IL-4 tg mice
anti-CD4
treated 11 111 111
IL-4 tg
anti-IL-4
treated 2 2 1/2
IL-4 tg 3
CTLA-4 tg
crosses 111 111 111
Summary of the autoimmune-type disorders detected in the IL-4 tg
mice crossed with CTLA-4 tg mice or treated with anti-IL-4 or anti-
CD4 antibodies. The development of anemia, glomerulonephritis and
Ig-depositions in the kidneys were determined for each individual
mouse per group (for details of treatment and detection see Materials
and Methods and Results). The severity of the disorder/group was
scored as follows: undetectable (2), detectable (1), mild (11), severe
(111).336 Autoimmune-type Disorders in IL-4 Transgenic Mice
terestingly, there was no difference between IL-4 tg mice
treated with the anti-CD4 antibodies and non treated IL-4
tg mice in respect to extramedullary hematopoiesis in spleen
and liver respectively. The IL-4 tg mice treated with anti-
CD4 antibodies also developed severe glomerulonephritis
(Table 3 and data not shown).
To further investigate the role of T cells in the develop-
ment of the autoimmune-like disease in IL-4 tg mice, we
crossed IL-4 tg mice with tg mice secreting a CTLA-4 hu-
man Ig fusion protein (CTLA-4 tg mice). The soluble
CTLA-4 human Ig fusion protein binds to the B71 and
B72 accessory molecules thus inhibiting T cell costimula-
tion via CD28 (18). This leads to the inability of T cells to
sufficiently activate B cells to produce antibodies due to the
lack of in vivo cytokine secretion by T cells (19). Compar-
ison of the F1 offspring from IL-4 tg 3 CTLA-4 tg cross-
ings (both heterozygous for the transgene) revealed that
5–6-wk-old double tg mice were suffering from anemia as
seen by the reduction of hematocrit counts (0.35 6 0.02 in
double IL-4/CTLA-4 tg mice [n 5 4] versus 0.34 6 0.07
[n 5 6] in IL-4 tg mice and 0.48 6 0.04 in single CTLA-4 tg
mice [n 5 5]). The double-tg mice also developed glomer-
ulonephritis with Ig deposits in the glomeruli (data not
shown).
To ascertain that the observed disorders were indeed due
to the expression of IL-4, we treated seven IL-4 tg and
nine littermate control mice with neutralizing anti-IL-4
antibodies. After 7 wk of antibody treatment, all of the
mice were healthy and none had died (Fig. 6 B). Further-
more, anti-IL-4–treated tg mice did not develop an anemia
as seen by the normal hematocrit levels (0.45 6 0.03 versus
0.48 6 0.04 in treated control mice) and the lack of ex-
tramedullary blood formation in the spleen and liver (data
not shown). Furthermore, kidneys of anti-IL-4 treated tg
mice showed no pathological changes by light microscopy
with only minor Ig deposits in the glomeruli (data not
shown). Table 3 summarizes the results obtained in IL-4 tg
mice using the different experimental approaches.
Discussion
A striking feature of the IL-4 tg mice used in this study is
that they have a high mortality rate and develop anemia
and glomerulonephritis. The glomerulonephritis is charac-
terized by proteinuria, and complement and Ig deposits in
the glomeruli. The antibodies present in the glomeruli
could either be directly binding to renal antigens or be part
of immune complex depositions. Whether these Ig deposi-
tions in the glomeruli are responsible for nephritis remains
to be determined, although together with the complement
binding, this seems to be the most likely explanation. The
kidney disease in the IL-4 tg animals was accompanied by
severe anemia. This was apparent by the very low hemat-
ocrit counts, high reticulocyte numbers in the blood, and
extramedullary hematopoiesis in liver and spleen. Mice
with high reticulocyte and low hematocrit counts had ele-
vated bilirubin levels in the serum, and in some cases, weak
autoantibody binding to the erythrocytes could be detected
(data not shown). This data suggest that the mice were suf-
fering from an AIHA. However, a coombs test using erythro-
cytes from the IL-4 tg mice failed to detect any autoantibody
binding. This suggests that anti-erythrocyte autoantibodies
were possibly not the cause for the hemolytic anemia ob-
served in the IL-4 tg mice. In humans, progressive renal
failure can lead to deficiency of erythropoietin production,
which may also cause anemia (26). Therefore it is possible
that the glomerulonephritis in the IL-4 tg mice was con-
tributing to the anemia. However, it is very unlikely that
renal failure was responsible for the initial development of
anemia in these mice, since both extramedullary blood for-
mation and increased production of reticulocytes is depen-
dent upon the action of erythropoietin. Taken together the
anemia detected in the IL-4 tg mice has many of the fea-
tures typical for an AIHA. However, we were not able to
readily detect autoantibodies binding to the erythrocytes
suggesting that the hemolytic anemia might be due to
other mechanisms. The treatment of the IL-4 tg mice with
anti-IL-4 antibodies completely abolished the development
of the observed anemia strongly suggesting that the anemia
was due to either a direct or indirect immunological mech-
anism mediated by IL-4.
It is not clear what is causing the high mortality of the
IL-4 tg mice. Severe anemia and glomerulonephritis in
IL-4 tg mice correlated with the onset of the wasting syn-
drome, with no detectable signs of bacterial or viral infec-
tions (by histology and blood cultures). Taken together,
these results strongly indicate that IL-4 tg mice die as a di-
rect result of an autoimmune-type disorder, although it is
not possible to completely rule out other causes of death.
The findings that IL-4 tg mice had higher autoantibody
levels and more detectable autoantibody producing B cells
in the spleen, together with the deposition of antibodies in
the kidney suggests that the increase in autoantibody levels
could be causing autoimmune disease leading to the ob-
served glomerulonephritis and anemia. In the murine ani-
mal models for SLE, anemia and glomerulonephritis are
usually mutually exclusive (1, 27). This is not true for hu-
man disease where individuals can suffer from both anemia
and glomerulonephritis (28). Because the IL-4 tg mice de-
velop both anemia and a glomerulonephritis it is possible
that these mice might be a very useful novel animal model
for human SLE disease.
What is the reason for this increase in self-reactive B cells?
One possibility is that the tg expression of IL-4 leads to the
generation of more self-reactive Th cells, which then in
turn activate and expand the small number of normally
present self-reactive B cells. The negative selection of su-
perantigen reactive T cells in the thymus and the periphery
was normal in the IL-4 tg mice. Therefore it is unlikely
that an increase in autoreactive T cells was responsible for
the generation of more self-reactive B cells.
Another possibility for the increase in autoantibody lev-
els is that the constitutive expression of IL-4 leads to poly-
clonal B cell activation. Polyclonal B cell activation has
been shown to lead to the production of autoantibodies
and autoimmune disease (22, 23). Our experiments clearly337 Erb et al.
show that the B cells in the IL-4 tg mice are hyperreactive,
as seen by the high level of MHC class II expression and
the greater reactivity to in vitro stimulation via anti-
mF(ab9)2  antibodies or CD40 ligand transfected L cells. The
addition of 10 mg/ml 11B11 (anti-IL-4 neutralizing anti-
bodies) had no effect on the in vitro proliferation of the B
cells from the IL-4 tg mice (Fig. 5) or B cells from the con-
trol animals (data not shown). This shows that the en-
hanced in vitro reactivity to B cell stimulators was due to
prior in vivo activation and not in vitro activation by tg-
derived IL-4. Furthermore, IgM and especially IgG1 and
IgE serum levels were greatly enhanced (16). Therefore,
polyclonal B cell activation could be a simple explanation
for the increase in autoantibody levels.
A further possibility which could explain how IL-4 leads
to increased development of autoreactive B cells in IL-4 tg
mice is that IL-4 selectively rescues autoreactive B cells
from cell death. This effect was described in vitro. It was
reported that cross-linking sIgM on immature bone mar-
row–derived B cells resulted in apoptotic cell death, and
that the sIgM-induced apoptosis could be blocked by the
addition of IL-4 (12). IL-4 also rescued mature B cells,
stimulated via plastic-immobilized anti-m or anti-d anti-
bodies from apoptosis, when it was added to the cultures in
conjunction with anti-CD40 antibodies (13). Furthermore,
immature B cells stimulated with anti-m, anti-IgD, and CD40
ligand–transfected fibroblasts, only proliferated when IL-4
was added to the culture (10). These in vitro assays mimic
the in vivo activation of potentially autoreactive B cells
through noncognate pathways in the presence of IL-4. The
expression of tg IL-4 in vivo could, as shown in vitro, se-
lectively rescue autoreactive B cells from apoptosis thus
causing the increase in autoantibody levels and the autoim-
mune-type disorders. To address this issue we crossed IL-4
tg mice with tg mice expressing genes for the variable re-
gion of an anti-H-2k antibody (3-83m tg mice [30]). The
resulting F1 single 3-83m tg mice and double tg mice, ex-
pressing both IL-4 and the 3-83m transgene, express H-2k
MHC class I molecules and should, therefore, delete the
anti-H-2k receptor bearing B cells. Our results showed that
virtually no anti-H-2k Ig receptor bearing B cells could be
detected in the bone marrow, lymph nodes, and spleen of
both the single 3-83m tg mice and 3-83m 3 IL-4 tg mice.
These results show that negative selection of self-reactive B
cells is normal in the IL-4 tg mice and using superantigen
induced T cell depletion as an indicator for normal nega-
tive selection of autoreactive T cells suggest that polyclonal
B cell activation is the most likely explanation for the in-
crease in autoantibody levels in the IL-4 tg mice.
To evaluate the role of CD41 T cells in the develop-
ment of the pathological disorders detected in IL-4 tg mice,
we treated the mice with deleting anti-CD4 antibodies for
8 wk. The increased survival (75% versus 45% in untreated
mice), suggests that CD41 T cells were contributing to dis-
ease exacerbation. However, anti-CD4–treated IL-4 tg mice
still developed severe anemia and glomerulonephritis sug-
gesting that CD41 T cells were not responsible for disease
development. To rule out the possibility that low numbers
of residual CD41 T cells (2%) present in the anti-CD4
treated mice had an effect on the development of autoim-
mune-like disorders, we crossed IL-4 tg with tg mice expres-
sing a soluble CTLA-4 human Ig fusion protein (CTLA-4
tg mice [18]). The soluble CTLA-4 binds to the B71 and
B72 accessory molecules thus inhibiting T cell costimula-
tion via CD28, leading to the inability of T cells to give
help to B cells (19). The double-tg mice expressing both
IL-4 and soluble CTLA-4 had a similar death rate, hemato-
crit counts and kidney damage, as did the mice only ex-
pressing IL-4 (Table 3 and data not shown). Together with
the data from the anti-CD4 treatment this argues that
CD41 T cell interaction with B cells was not necessary for
the generation of the disorders detected in the IL-4 tg
mice.
The treatment of the IL-4 tg mice with neutralizing
anti-IL-4 antibodies (11B11) clearly showed that develop-
ment of the pathological disorders were due to expression
of IL-4. Surprisingly, it has not been previously reported
that other IL-4 tg mice models, where B cells and/or T cells
expressed tg IL-4 (31–33), develop autoimmune-like dis-
ease. The reason for this discrepancy between our model
and the other tg models is not clear, but probably reflects
the different expression patterns of IL-4 in the different
mouse lines. However, although there is no evidence sug-
gesting that other IL-4 tg mice models develop autoim-
mune-like disease, two recent reports demonstrated that the
development of autoimmunity was associated with the pro-
duction of IL-4. In a murine model of graft versus host dis-
ease, anti-IL4 antibody treatment prevented development of
disease (34). Furthermore, autoimmune disorders develop-
ing after neonatal thymectomy have also been reported
to be associated with IL-4 production and a humoral im-
mune response (35). These two reports demonstrate in-
volvement of in vivo IL-4 production and development of
autoimmune disease, and  support our findings that the in-
appropriate expression of IL-4 can under some circum-
stances lead to autoimmune-like disorders. However, in
these two models disease development was dependent on
CD41 T cells. This does not seem to be the case in our
model. We therefore suggest that the presence of IL-4
alone (in sufficient amounts and at the appropriate place)
might be able to substitute for self-reactive CD41 T cells
secreting IL-4, leading to increased levels of autoantibodies
and the development of autoimmune disease.
In conclusion, our results demonstrate that the constitu-
tive in vivo expression of IL-4 leads to the activation and/
or expansion of autoreactive B cells and development of
autoimmune-type disease. From our data we cannot con-
clude whether autoantibodies were indeed causing the de-
tected anemia and glomerulonephritis; however, it seems
the most likely explanation. It has been proposed that re-
combinant IL-4 could be used for treatment of Th1 medi-
ated inflammatory autoimmune diseases in humans (36).
Immune deviation mediated by IL-4 might prove very use-
ful for treatment of some of these disorders, but in view of
our results, the possible effects of IL-4 treatment on hu-
mans should be further scrutinized.338 Autoimmune-type Disorders in IL-4 Transgenic Mice
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